Development of a First-In-Class Oral KCC2 potentiator for Treating Chronic Pain: Advancing Precision Analgesics for Novel CNS Targets
- Developing a non-opioid, first-in-class mechanism that a central nervous system-specific target to alleviate pain, without the side effects associated with existing analgesics
- KCC2 potentiation is a novel approach to address CNS sensitization-driven pain, and enables precision analgesic approaches in pain populations. KCC2 potentiators have analgesic efficacy and address spinal disinhibition pathology in pain
- Axonis first-in-class oral KCC2 potentiator, AXN-027, is advancing into Phase 1b/2a trials for treating pain